State of New Jersey Common Pension Fund D Lowers Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

State of New Jersey Common Pension Fund D lowered its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) by 6.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 78,484 shares of the specialty pharmaceutical company’s stock after selling 5,431 shares during the period. State of New Jersey Common Pension Fund D owned 0.15% of Supernus Pharmaceuticals worth $2,537,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. Campbell Newman Asset Management Inc. lifted its holdings in Supernus Pharmaceuticals by 2.0% during the first quarter. Campbell Newman Asset Management Inc. now owns 22,696 shares of the specialty pharmaceutical company’s stock worth $734,000 after buying an additional 443 shares during the period. Maryland State Retirement & Pension System grew its stake in Supernus Pharmaceuticals by 2.2% during the 1st quarter. Maryland State Retirement & Pension System now owns 21,511 shares of the specialty pharmaceutical company’s stock worth $695,000 after buying an additional 460 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in Supernus Pharmaceuticals by 2.5% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 20,200 shares of the specialty pharmaceutical company’s stock valued at $605,000 after buying an additional 500 shares in the last quarter. Veriti Management LLC raised its stake in Supernus Pharmaceuticals by 8.8% in the first quarter. Veriti Management LLC now owns 8,903 shares of the specialty pharmaceutical company’s stock valued at $288,000 after buying an additional 720 shares during the last quarter. Finally, FDx Advisors Inc. boosted its holdings in Supernus Pharmaceuticals by 10.4% in the first quarter. FDx Advisors Inc. now owns 7,766 shares of the specialty pharmaceutical company’s stock worth $251,000 after acquiring an additional 733 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have recently issued reports on SUPN shares. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 18th. TheStreet cut shares of Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Monday, April 18th.

Supernus Pharmaceuticals Stock Down 0.8 %

Shares of SUPN stock opened at $31.50 on Tuesday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $34.50. The firm has a market capitalization of $1.68 billion, a PE ratio of 24.42 and a beta of 1.04. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.69 and a current ratio of 2.00. The stock’s 50-day simple moving average is $28.72 and its 200-day simple moving average is $29.73.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last issued its earnings results on Monday, May 9th. The specialty pharmaceutical company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.17. The firm had revenue of $152.50 million for the quarter, compared to analyst estimates of $150.47 million. Supernus Pharmaceuticals had a return on equity of 9.05% and a net margin of 12.20%. Supernus Pharmaceuticals’s revenue for the quarter was up 16.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.11 earnings per share. Equities analysts expect that Supernus Pharmaceuticals, Inc. will post 1.64 earnings per share for the current year.

Supernus Pharmaceuticals Profile

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Featured Articles

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Want More Great Investing Ideas?

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.